A new target for potential treatments for blast phase myeloproliferative neoplasm (BP-MPN), one of the most aggressive forms of leukemia, has been identified by a research team at the University of ...

Intensive chemotherapy provided the longest overall and progression-free survival, especially in blast phase MPN patients. Venclexta-based treatments did not significantly improve progression-free ...

The ELN 2024 framework offers better stratification for AP/BP MPN, but gaps remain between intermediate and adverse groups. The study analyzed 211 patients, showing modest response rates and ...

MPN-BP transformation is driven by sequential mutations disrupting genomic stability, with TP53 mutations being strong predictors of progression. TP53 mutations confer a selective growth advantage, ...

A subset of patients with myeloproliferative neoplasms (MPNs) -- clonal disorders of hematopoietic stem cells that include polycythemia vera and essential thrombocythemia, as well as primary ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...